IRCT20120215009014N467 IRCT 2023-04-04 Hamedan University of Medical Sciences Effect of Sylimarin versus placebo on the reduction of liver complication of Teriflunomide in patients with multiple sclerosis Effect of Sylimarin versus placebo on the reduction of liver complication of Teriflunomide in patients with multiple sclerosis: a double-blind randomized clinical trial 2023-04-21 anticipated 42 Complete https://irct.ir/trial/69402 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random assignment of the patients to the intervention and control groups through the drawing of lots. To do this, we prepare two sheets and write "intervention" on one sheet and "control" on another. Then, by referring each patient, one of the sheets will be randomly taken and the patient will be assigned to the intervention or control group, Blinding description: The shape of the medications and placebos will be perfectly the same. Therefore, patients will be unaware of the type of intervention. The person who performs the randomization will be different from the person who examines the patients, so the person who examines the patients will not be aware of the intervention. Thus, the trial will be run as double-blind. 3 Multiple sclerosis. Intervention 1: Intervention group: Triflunomide tablet 14 mg daily plus silymarin tablet 140 mg twice daily for 2 months. Intervention 2: Control group: Triflunomide tablet 14 mg daily plus placebo tablet (starch) twice a day for 2 months. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is It depends on the situation and the results of the study as well as the approval of the financial supporting organization.